Medical Oncology

Michael Aaron Morse, MD

Professor of Medicine
Professor in the Department of Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 3233, Durham, NC 27710
Phone (919) 681-3480
Email address morse004@mc.duke.edu

We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.

Our current clinical trials include phase I and II studies of immunotherapy for: patients with metastatic malignancies expressing CEA, pancreatic cancer, colorectal cancer, breast cancer, and ovarian cancer, and leukemias following HSCT. My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.

Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1993 - 1996
  • Medical Resident, Medicine, University of Washington, 1990 - 1993
  • M.D., Yale University, 1990

Grants

Publications

Fishman, M, Dutcher, JP, Clark, JI, Alva, A, Miletello, GP, Curti, B, Agarwal, N, Hauke, R, Mahoney, KM, Moon, H, Treisman, J, Tykodi, SS, Daniels, G, Morse, MA, Wong, MKK, Kaufman, H, Gregory, N, and McDermott, DF. "Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry." Journal for Immunotherapy of Cancer 7, no. 1 (March 27, 2019): 84-null.

PMID
30917871
Full Text

Wang, X, Wang, S, Morse, MA, Jiang, N, Zhao, Y, Song, Y, Zhou, L, Huang, H, Zhou, X, Hobeika, A, Ren, J, and Lyerly, HK. "Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients." Journal of Thrombosis and Thrombolysis (March 22, 2019).

PMID
30903459
Full Text

Qiao, G, Wang, X, Zhou, L, Zhou, X, Song, Y, Wang, S, Zhao, L, Morse, MA, Hobeika, A, Song, J, Yi, X, Xia, X, Ren, J, and Lyerly, HK. "Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 25, no. 5 (March 2019): 1494-1504.

PMID
30514775
Full Text

Chawla, SP, Bruckner, H, Morse, MA, Assudani, N, Hall, FL, and Gordon, EM. "A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer." Molecular Therapy Oncolytics 12 (March 2019): 56-67.

PMID
30705966
Full Text

Wang, J, Ren, X-R, Piao, H, Zhao, S, Osada, T, Premont, RT, Mook, RA, Morse, MA, Lyerly, HK, and Chen, W. "Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy." The Biochemical Journal 476, no. 3 (February 8, 2019): 535-546.

PMID
30635359
Full Text

Morse, MA, Sun, W, Kim, R, He, AR, Abada, PB, Mynderse, M, and Finn, RS. "The Role of Angiogenesis in Hepatocellular Carcinoma." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 25, no. 3 (February 2019): 912-920. (Review)

PMID
30274981
Full Text

Crosby, EJ, Gwin, W, Blackwell, K, Marcom, PK, Chang, S, Maecker, HT, Broadwater, G, Hyslop, T, Kim, S, Rogatko, A, Lubkov, V, Snyder, JC, Osada, T, Hobeika, AC, Morse, MA, Lyerly, HK, and Hartman, ZC. "Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research (January 11, 2019).

PMID
30635338
Full Text

Kane, A, Thorpe, MP, Morse, MA, Howard, BA, Oldan, JD, Zhu, J, Wong, TZ, Petry, NA, Reiman, R, and Borges-Neto, S. "Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 59, no. 11 (November 2018): 1708-1713.

PMID
29777005
Full Text

Zhao, Y, Qiao, G, Wang, X, Song, Y, Zhou, X, Jiang, N, Zhou, L, Huang, H, Zhao, J, Morse, MA, Hobeika, A, Ren, J, and Lyerly, HK. "Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS)." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (October 29, 2018).

PMID
30374838
Full Text

Marano, AL, Clarke, JM, Morse, MA, Shah, A, Barrow, W, Selim, MA, Hall, RP, and Cardones, AR. "Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy." The British Journal of Dermatology (September 23, 2018).

PMID
30244487
Full Text

Pages